132 related articles for article (PubMed ID: 37622659)
1. Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient.
Xará J; Relvas M; Figueiredo C; Calvão J; Batista M; Ramos L
Int J Dermatol; 2023 Dec; 62(12):e617-e618. PubMed ID: 37622659
[No Abstract] [Full Text] [Related]
2. Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
Yang DY; Jing WW; Liu X; Li L; Lu T; Li XL
Adv Skin Wound Care; 2024 Feb; 37(2):1-4. PubMed ID: 38241457
[TBL] [Abstract][Full Text] [Related]
3. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Vasilev P; Kalev D; Karamanliev M; Dimitrov D; Troyanova P; Yordanova I
J Dtsch Dermatol Ges; 2023 Mar; 21(3):295-297. PubMed ID: 36855845
[No Abstract] [Full Text] [Related]
4. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab.
Caroppo F; Milan E; Giulioni E; Belloni Fortina A
J Eur Acad Dermatol Venereol; 2022 May; 36(5):e365-e367. PubMed ID: 34927769
[No Abstract] [Full Text] [Related]
5. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report.
Wang Y; Zhou M; Zhang L; Zheng S; Hong Y; Gao XH
Dermatol Ther; 2021 Nov; 34(6):e15130. PubMed ID: 34528352
[No Abstract] [Full Text] [Related]
6. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.
Shao L; Zhong DQ; Liu YM; Wang JQ
Int J Dermatol; 2023 Oct; 62(10):e542-e545. PubMed ID: 37326291
[No Abstract] [Full Text] [Related]
7. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.
Yu L; Wang J; Bian L; Li Z; Li M; Li J; Zhang S
Dermatitis; 2023; 34(1):58-59. PubMed ID: 36705654
[No Abstract] [Full Text] [Related]
8. Epidermolysis bullosa pruriginosa treated with dupilumab.
Zhou AG; Little AJ; Antaya RJ
Pediatr Dermatol; 2021 Mar; 38(2):526-527. PubMed ID: 33336814
[TBL] [Abstract][Full Text] [Related]
9. Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab.
Roque Quintana B; Piqué Durán E; Pérez Cejudo JA
Actas Dermosifiliogr; 2024 Feb; 115(2):184-186. PubMed ID: 36871818
[No Abstract] [Full Text] [Related]
10. A case of junctional epidermolysis bullosa intermediate with collagen XVII deficiency treated with dupilumab.
Zhang L; Wang S; Chen Q; Xiang L
J Dermatolog Treat; 2023 Dec; 34(1):2253943. PubMed ID: 37968922
[TBL] [Abstract][Full Text] [Related]
11. Successful use of rituximab, an anti-CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa.
Hunjan MK; Bardhan A; Harper N; Langman G; Ajayi B; Suresh V; Heagerty AHM
Clin Exp Dermatol; 2022 Aug; 47(8):1588-1590. PubMed ID: 35426452
[TBL] [Abstract][Full Text] [Related]
12. Reply to 'A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab' by Caroppo et al.
Martora F; Fabbrocini G; Nappa P; Marasca C; Patruno C; Scalvenzi M; Napolitano M
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e729-e730. PubMed ID: 35604042
[No Abstract] [Full Text] [Related]
13. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
[No Abstract] [Full Text] [Related]
14. Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa.
Welponer T; Diem A; Nahler G; Laimer M
Indian J Dermatol Venereol Leprol; 2022; 88(4):551-552. PubMed ID: 35593277
[No Abstract] [Full Text] [Related]
15. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.
Shehadeh W; Sarig O; Bar J; Sprecher E; Samuelov L
Br J Dermatol; 2020 Jun; 182(6):1495-1497. PubMed ID: 31899820
[No Abstract] [Full Text] [Related]
16. Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Reimer A; Lu S; He Y; Bruckner-Tuderman L; Technau-Hafsi K; Meiss F; Has C; von Bubnoff D
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):e1-e3. PubMed ID: 31374134
[No Abstract] [Full Text] [Related]
17. Dominant dystrophic epidermolysis bullosa with congenital absence of skin and brachydactyly of the great toes.
Sawka E; Funk T
Pediatr Dermatol; 2021 Sep; 38(5):1251-1254. PubMed ID: 34338359
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab.
Wu XG; Yan S; Jiang JQ; Zhou TT; Fang X; Yang H; Bai XM; Wang H; Luo X
J Dermatol; 2023 Jun; 50(6):837-842. PubMed ID: 36694424
[TBL] [Abstract][Full Text] [Related]
19. Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases.
Relvas M; Figueiredo AC; Calado R; Calvão J; Ramos L
Dermatol Ther; 2022 Sep; 35(9):e15678. PubMed ID: 35770627
[No Abstract] [Full Text] [Related]
20. Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association.
Matard B; Bourrat E; Cavalié M; Chiaverini C; Reygagne P
Br J Dermatol; 2022 Dec; 187(6):1026-1028. PubMed ID: 35904062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
